Focus: Lonza is a global CDMO (Contract Development and Manufacturing Organization) headquartered in Basel, Switzerland, serving biopharmaceutical clients across multiple therapeutic modalities. With 10,001–50,000 employees and a public listing (LONN), it operates at enterprise scale in the outsourced manufacturing sector.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Hot — 1370 jobs added in 30d
Net +972 (1370 new, 398 removed). Aggressive expansion phase.
Lonza is a stable, scaling CDMO with strong operational hiring—ideal for manufacturing, QA, and engineering careers; less appealing for those seeking early-stage drug development or scientific leadership roles.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Lonza
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lonza's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Lonza Group AG stock: What the latest market data says - AD HOC NEWS
Lonza Group AG stock: What the latest market data says AD HOC NEWS
Lonza Group AG stock (CH0013841017): CDMO player back in focus after April 2026 results and share mo - AD HOC NEWS
Lonza Group AG stock (CH0013841017): CDMO player back in focus after April 2026 results and share mo AD HOC NEWS
Stipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter
Stipple Bio taps Lonza platform to advance ADC pipeline The Pharma Letter
Lonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post
Lonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies Indian Pharma Post
Lonza, Stipple Bio Sign ADC Licensing Deal - Contract Pharma
Lonza, Stipple Bio Sign ADC Licensing Deal Contract Pharma
Lonza Group AG stock (CH0013841017): shares steady in Zurich as investors await next catalysts - AD HOC NEWS
Lonza Group AG stock (CH0013841017): shares steady in Zurich as investors await next catalysts AD HOC NEWS
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Sequential digestions enable identification and quantification of rapid aspartic acid isomerization in the CDR of a monoclonal antibody light chain.
Disulfide bond reduction of antibodies during clarification: A bench-scale assay and a mitigation tool.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo